IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers.

ABSTRACT:

Background

Asthma with neutrophil predominance is challenging to treat with corticosteroids. Novel treatment options for asthma include those that target innate immune activity. Recent literature has indicated a significant role for IL-1β in both acute and chronic neutrophilic asthma.

Objective

This study used inhaled endotoxin (LPS) challenge as a model of innate immune activation to (1) assess the safety of the IL-1 receptor antagonist anakinra in conjunction with inhaled LPS and (2) to test the hypothesis that IL-1 blockade will suppress the acute neutrophil response to challenge with inhaled LPS.

Methods

In a phase I clinical study 17 healthy volunteers completed a double-blind, placebo-controlled crossover study in which they received 2 daily subcutaneous doses o

SUBMITTER: Hernandez ML 

PROVIDER: S-EPMC4323893 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature